Asker Healthcare Group AB (publ) (STO:ASKER)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 27.92B |
| Revenue (ttm) | 16.79B |
| Net Income (ttm) | 492.00M |
| Shares Out | 383.04M |
| EPS (ttm) | 1.34 |
| PE Ratio | 54.56 |
| Forward PE | 25.25 |
| Dividend | 0.39 (0.53%) |
| Ex-Dividend Date | n/a |
| Volume | 290,208 |
| Average Volume | 411,641 |
| Open | 72.85 |
| Previous Close | 72.90 |
| Day's Range | 71.15 - 73.05 |
| 52-Week Range | 58.64 - 131.22 |
| Beta | n/a |
| RSI | 50.40 |
| Earnings Date | Apr 16, 2026 |
About Asker Healthcare Group AB
Asker Healthcare Group AB (publ) provides medical supplies, devices, and equipment and related solutions that support patient care. The company supplies and distributes fittings and equipment; veterinary equipment; surgical and diagnostic instruments; medical supplies and equipment for urology, ultrasound diagnostics, laser treatment, and regenerative medicine; medical equipment for operating rooms, polyclinics, and day surgeries; hygiene equipment; equipment and products for beauty clinics; defibrillators and wound care products. In addition, ... [Read more]
Financial Performance
In 2025, Asker Healthcare Group AB's revenue was 16.79 billion, an increase of 11.73% compared to the previous year's 15.03 billion. Earnings were 492.00 million, an increase of 36.67%.
Financial StatementsNews
Asker Healthcare Group AB (FRA:I88) Q4 2025 Earnings Call Highlights: Strong Sales Growth and ...
Asker Healthcare Group AB (FRA:I88) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Expansion Amid Challenges
Q4 2025 Asker Healthcare Group AB Earnings Call Transcript
Q4 2025 Asker Healthcare Group AB Earnings Call Transcript
Asker Healthcare Group AB Earnings Call Transcript: Q4 2025
Q4 saw 9% sales growth and a 16% rise in adjusted EBITA, with strong results in West and Central, and a 10% EBITDA margin achieved. Fourteen acquisitions expanded the footprint to 19 markets, and leverage remains stable, supporting continued M&A and a proposed 30% dividend.
Asker Healthcare To Acquire Allion Healthcare
(RTTNews) - Asker Healthcare Group AB (ASKER.ST), on Tuesday announced that it has signed an agreement to acquire shares of Allion Healthcare Inc. (ALLI), a manufacturer and distributor of medical sup...
Asker Healthcare Group AB (FRA:I88) Q3 2025 Earnings Call Highlights: Robust Growth and ...
Asker Healthcare Group AB (FRA:I88) Q3 2025 Earnings Call Highlights: Robust Growth and Strategic Acquisitions Drive Performance
Q3 2025 Asker Healthcare Group AB Earnings Call Transcript
Q3 2025 Asker Healthcare Group AB Earnings Call Transcript
Asker Healthcare Group AB Earnings Call Transcript: Q3 2025
Q3 saw 25% earnings growth and 15% sales growth, with strong results in West and Central, and a robust M&A pipeline. Leverage remains within target, and underlying organic growth is solid across regions, despite lumpy defense sales in North.
Asker Healthcare Acquires InnoMedicus; Expects To Contribute Positively To EBITA Margin
(RTTNews) - Asker Healthcare Group (ASKER.ST) has acquired 100 percent of the shares in InnoMedicus AG, a distributor specialising in devices and solutions for precise diagnostics and minimally invasi...
Asker Healthcare Group AB Earnings Call Transcript: Q2 2025
Q2 saw 12% adjusted EBITDA growth (after FX), 9% sales growth, and a 9.5% EBITDA margin, with strong M&A activity and a robust pipeline. Region West and Central delivered strong results, while North faced headwinds from lower project-based sales.
Asker Healthcare Group AB Earnings Call Transcript: Q1 2025
Q1 delivered 16% sales and 17% adjusted EBITDA growth, with strong organic and M&A contributions. The IPO strengthened the balance sheet, enabling continued acquisition activity, while margins and key metrics improved toward targets.